Convergence Investment Partners LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 78.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 40,292 shares of the company’s stock after purchasing an additional 17,734 shares during the quarter. Merck & Co., Inc. makes up 0.8% of Convergence Investment Partners LLC’s portfolio, making the stock its 28th biggest holding. Convergence Investment Partners LLC’s holdings in Merck & Co., Inc. were worth $4,241,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in MRK. D.A. Davidson & CO. increased its stake in Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after acquiring an additional 24,576 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Merck & Co., Inc. by 48.9% in the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after buying an additional 32,114 shares during the period. Coldstream Capital Management Inc. boosted its position in shares of Merck & Co., Inc. by 12.7% in the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after buying an additional 13,940 shares during the period. NEOS Investment Management LLC boosted its position in shares of Merck & Co., Inc. by 39.9% in the third quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock worth $29,181,000 after buying an additional 99,074 shares during the period. Finally, Campbell Capital Management Inc. purchased a new stake in shares of Merck & Co., Inc. in the third quarter worth about $1,866,000. 76.07% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on MRK. Guggenheim upped their target price on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research report on Friday, February 13th. Finally, Barclays began coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.
Merck & Co., Inc. Trading Down 1.8%
Shares of MRK opened at $111.36 on Friday. The company has a market capitalization of $275.03 billion, a P/E ratio of 31.37, a P/E/G ratio of 2.55 and a beta of 0.18. Merck & Co., Inc. has a one year low of $74.37 and a one year high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock has a 50-day moving average price of $116.00 and a 200 day moving average price of $109.21.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
